Results 201 to 210 of about 310,818 (241)

ESR1 Variants and Subcontinental Genomic Ancestry: Insights from the 1000 Genomes Project and Native American Populations

Clinical Pharmacology &Therapeutics, EarlyView.
The ESR1 gene is relevant in breast cancer treatments in the pharmacogenetics context. However, Native, African, and mixed populations are known to be underrepresented in genomic studies. This is particularly important given that the difference in variants' frequencies among different populations can lead to population‐specific clinical implications ...
Mariana M. Scudeler, Caíque Manóchio, Bruno Miwa, Guilherme Belfort‐Almeida, Lucas Faria‐Costa, Cesar Sanchez, Carlos Padilla, Omar Caceres, Eduardo Tarazona‐Santos, Heinner Guio, Timothy D. O'Connor, Fernanda Rodrigues‐Soares   +11 more
wiley   +1 more source

Implementing Pre‐Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects

Clinical Pharmacology &Therapeutics, EarlyView.
In pediatric oncology, pharmacogenetic guidelines are underutilized and the potential impact of pre‐emptive pharmacogenetic screening remains largely unexplored despite this field's need for individualized approaches. While comprehensive pharmacogenetic guidelines are not yet available for all anticancer drugs, evidence‐based recommendations exist for ...
Emma C. Bernsen, Eugène T.P. Verwiel, Maaike van der Lee, Jesse J. Swen, Marcel Santoso, Leiah J. Brigitha, Rick Admiraal, Bastiaan B.J. Tops, Alwin D.R. Huitema, Patrick Kemmeren, Jayne Y. Hehir‐Kwa, Lidwien M. Hanff, Meta H.M. Diekstra   +12 more
wiley   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

Standardization of Suspension and Imaging Mass Cytometry Single‐Cell Readouts for Clinical Decision Making

Cytometry Part A, EarlyView.
ABSTRACT Suspension and imaging mass cytometry are single‐cell, proteomic‐based methods used to characterize tissue composition and structure. Data assessing the consistency of these methods over an extended period of time are still sparse and are needed if mass cytometry‐based methods are to be used clinically.
Ruben Casanova, Shuhan Xu, Pierre Bost, Sujana Sivapatham, Andrea Jacobs, Stefanie Engler, Tumor Profiler Consortium, Rudolf Aebersold, Melike Ak, Faisal S Al‐Quaddoomi, I Albert Silvana, Jonas Albinus, Ilaria Alborelli, Sonali Andani, Per‐Olof Attinger, Marina Bacac, Daniel Baumhoer, Beatrice Beck‐Schimmer, Niko Beerenwinkel, Christian Beisel, Lara Bernasconi, Anne Bertolini, Bernd Bodenmiller, Ximena Bonilla, Lars Bosshard, Byron Calgua, Ruben Casanova, Stéphane Chevrier, Natalia Chicherova, Ricardo Coelho, Maya D’Costa, Esther Danenberg, Natalie R Davidson, Monica‐Andreea Drăgan, Reinhard Dummer, Stefanie Engler, Martin Erkens, Katja Eschbach, Cinzia Esposito, André Fedier, Pedro F Ferreira, Joanna Ficek‐Pascual, Anja L Frei, Bruno Frey, Sandra Goetze, Linda Grob, Gabriele Gut, Detlef Günther, Pirmin Haeuptle, Viola Heinzelmann‐Schwarz, Sylvia Herter, Rene Holtackers, Tamara Huesser, Alexander Immer, Anja Irmisch, Francis Jacob, Andrea Jacobs, Tim M Jaeger, Katharina Jahn, Alva R James, Philip M Jermann, André Kahles, Abdullah Kahraman, Viktor H Koelzer, Werner Kuebler, Jack Kuipers, Christian P Kunze, Christian Kurzeder, Kjong‐Van Lehmann, Mitchell Levesque, Ulrike Lischetti, Flavio C Lombardo, Sebastian Lugert, Gerd Maass, Markus G Manz, Philipp Markolin, Martin Mehnert, Julien Mena, Julian M Metzler, Nicola Miglino, Emanuela S Milani, Holger Moch, Simone Muenst, Riccardo Murri, Charlotte KY Ng, Stefan Nicolet, Marta Nowak, Monica Nunez Lopez, Patrick GA Pedrioli, Lucas Pelkmans, Salvatore Piscuoglio, Michael Prummer, Laurie Prélot, Natalie Rimmer, Mathilde Ritter, Christian Rommel, María L Rosano‐González, Gunnar Rätsch, Natascha Santacroce, Jacobo Sarabia del Castillo, Ramona Schlenker, Petra C Schwalie, Severin Schwan, Tobias Schär, Gabriela Senti, Wenguang Shao, Franziska Singer, Sujana Sivapatham, Berend Snijder, Bettina Sobottka, Vipin T Sreedharan, Stefan Stark, Daniel J Stekhoven, Tanmay Tanna, Alexandre PA Theocharides, Tinu M Thomas, Markus Tolnay, Vinko Tosevski, Nora C Toussaint, Mustafa A Tuncel, Marina Tusup, Audrey Van Drogen, Marcus Vetter, Tatjana Vlajnic, Sandra Weber, Walter P Weber, Rebekka Wegmann, Michael Weller, Fabian Wendt, Norbert Wey, Andreas Wicki, Mattheus HE Wildschut, Bernd Wollscheid, Shuqing Yu, Johanna Ziegler, Marc Zimmermann, Martin Zoche, Gregor Zuend, Mitchell P. Levesque, Reinhard Dummer, Bernd Bodenmiller, Stéphane Chevrier   +141 more
wiley   +1 more source

Plasma levels of Human Granulocytic Elastase-alpha-Proteinase Inhibitor Complex (E-alpha1PI) in Leukemia [PDF]

, 1984
Hiller, E., Jochum, Marianne
core  

Some of the next articles are maybe not open access.

Related searches:

Acute Leukemia

DeckerMed Transitional Year Weekly Curriculum™, 2021
The acute leukemias are malignant clonal disorders characterized by aberrant differentiation and proliferation of transformed hematopoietic progenitor cells. These cells accumulate within the bone marrow and lead to suppression of the production of normal blood cells, with resulting symptoms from varying degrees of anemia, neutropenia, and ...
Roland B Walter, Richard A. Larson
openaire   +1 more source

Acute Leukemia

Hematology/Oncology Clinics of North America, 2014
Although great progress has been made in the understanding and treatment of acute leukemia, this disease has not been conquered. For emergency providers (EPs), the presentation of these patients to an emergency department presents a host of challenges.
Hayley, Rose-Inman, Damon, Kuehl
openaire   +3 more sources

Acute leukemia

Clinics in Laboratory Medicine, 2002
This article provides a review of the acute leukemias with updated basic and practical information. The main emphasis is on techniques used to arrive at the correct diagnosis. Although morphology and cytochemistry were the mainstays of diagnosis in the past, new developments in immunophenotyping, cytogenetics, molecular biology, and in vitro assays ...
Harold R, Schumacher, Carmelita J, Alvares, Ruthann I, Blough, Fermina, Mazzella   +3 more
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2008
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal transformation of hematopoietic precursors through the acquisition of chromosomal rearrangements and multiple gene mutations. As a result of highly collaborative clinical research by pediatric cooperative cancer groups worldwide, disease-free survival has ...
Jeffrey E, Rubnitz, Brenda, Gibson, Franklin O, Smith   +2 more
openaire   +4 more sources